Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes withdrawls or drug discontinuation due to adverse events during 24… compared with placebo? (very low certainty).
1 finding from 1 review
OR 2.43 [0.91, 6.49]
Studies not reported
Very low
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower alemtuzumab No direct evidence (moderate certainty).
1 finding from 1 review
OR 0.39 [0.19, 0.79]
Studies not reported
Moderate
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 54 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 54 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in cladribine (Direct evidence; 1 RCT; 1326 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab (Direct evidence; 1 RCT; 600 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher daclizumab (Direct evidence; 1 RCT; 600 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher fingolimod (Direct evidence; 2 RCTs; 2355 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 4 RCTs; 2419 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher glatiramer acetate (Direct evidence; 4 RCTs; 2419 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 3 RCTs; 243 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes immunoglobulins (Direct evidence; 3 RCTs; 243 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
OR 3.02 [0.27, 33.65]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to higher interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) (moderate certainty).
1 finding from 1 review
OR 1.48 [0.99, 2.2]
1 study · 2 participants
Moderate
Intervention not reported
Laquinimod (Direct evidence; 3 RCTs; 3457 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in laquinimod (Direct evidence; 3 RCTs; 3457 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (very low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 939 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in natalizumab (Direct evidence; 1 RCT; 939 participants) (moderate certainty).
1 finding from 1 review